Join AMCP Foundation for this National P&T Competition Training webinar. Our content expert will share best practices that managed care professionals would follow when developing drug monographs. If you're planning to participate in the 2024 P&T Competition, you don't want to miss these insights! This webinar will be hosted live on Zoom, with an opportunity to pose questions at the end of the presentation. A recorded version of the webinar will be posted on the AMCP Foundation website within 10 days of the live program. Competitors, student pharmacists, and all interested individuals are welcome to register.

Urinary tract infections (UTIs) are among the most common bacterial infections encountered in the ambulatory care setting in the United States. Rates of E. Coli resistance to some commonly prescribed treatments for community-acquired uncomplicated UTIs are high in some regions in the US, attributing to treatment failure. Recent evidence has shown that approximately 12% to 17% of patients diagnosed with an uncomplicated UTI experienced failure to empiric treatment for various reasons. Understanding those factors that may place a patient at higher risk of treatment failure can help to guide appropriate treatment. This program will provide disease education for population-based decision makers to inform on AMR in uncomplicated UTI, risk of treatment failure, and clinical and economic consequences of treatment failure.

Learning Objectives:

• Define uncomplicated UTI and review current management
• Inform on rates of antimicrobial resistance to common pathogens in community-acquired uncomplicated UTI
• Describe risk factors for treatment failure in uncomplicated UTI and clinical and economic consequences of failure
• Discuss how antimicrobial stewardship is an important part of addressing AMR challenges

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Elevar Therapeutics.

You are invited to attend a virtual PIE webinar about a new investigational treatment for unresectable or metastatic hepatocellular carcinoma (uHCC): Rivoceranib + Camrelizumab.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

This non-promotional, sponsored webinar will review health plan best practice recommendations for Chronic Lymphocytic Leukemia (CLL) with an impressive panel of oncology and managed care experts.

As managed care and payer professionals play a central role in improving value in and access to cancer care, understanding best practices in CLL that address the multidimensional system challenges can support identifying which health services are safe, efficacious, and cost-effective, address barriers to high-quality care, and better understand the patient experience in the health care system.

In this webinar, a panel of experts will discuss health plan best practices related to CLL, national managed care oncology professional survey results, and components of high-quality care that can improve health equity and address unmet needs in CLL. Following the presentation, join the panelists for a live Q&A session.

In this webinar, a panel of experts discuss health plan best practices related to continuous glucose monitoring. Following the presentation, join the panelists for a live Q&A session.

Learn About:

At the completion of this activity, participants should be able to:

• Explore health plan practices for the treatment of CLL
• Discuss key insights from a national managed care oncology survey on the treatments for CLL
• Examine strategies available to managed care professionals to guide treatment for CLL
• Identify components of high-quality care that improve health equity and address unmet needs in cancer care

This webinar explores the evolution of the treatment landscape, clinical outcomes, and practical management of a BCL2-Inhibitor. The content of this webinar is intended for US Formulary Decision Makers.

Learning Objectives:

• Review the AML disease state and evolving treatment landscape.
• Describe the efficacy and safety of BCL2-inhibitor treatment in newly diagnosed AML unfit for intensive chemotherapy.
• Provide an overview of the practical management of AML patients receiving BCL2-inhibitor treatment.

This expert-led webinar will explore the state of HCV in the United States, testing and treatment recommendations, key barriers to HCV treatment access and their impacts, how payers benefit from expanding HCV treatment access, treatment considerations for today's complex HCV population, and a treatment option that addresses many of the needs of today's patient population.

Nearly a decade after the development of direct-acting antiviral treatments that can cure HCV in more than 95% of people infected, only a small fraction of the 2.5 million people with chronic HCV in the United States have received treatment, and tens of thousands still die from the disease every year. This expert-led webinar will highlight:

• How many people in the United States have HCV and what percentage are diagnosed and treated
• Which patients are currently most likely to be infected with HCV
• HCV screening and treatment recommendations from major medical organizations
• Major barriers to HCV treatment and which patients are most impacted by them
• Benefits for payers of expanding HCV treatment access
• Important treatment considerations for today's complex chronic HCV patient population, including common comorbidities, concomitant medications, and lifestyle factors
• A treatment option for HCV that addresses many of the needs of today's patient population

Crohn’s Disease is a chronic, progressive, inflammatory bowel disease that damages the bowel over time and may result in decreased quality of life, hospitalizations, surgeries, and disability.  The American Gastroenterological Association treatment guidelines for moderate to severe Crohn’s Disease have been updated and new long-term goals for the management of the disease have been established.

Clinical advancement of the treatment of moderate to severe Crohn’s Disease have included therapeutic options with diverse mechanisms of action.  Head-to-head trials play an important role in advancing the science for HCPs and HCDMs responsible for the treatment of patients with Crohn’s Disease.  The SEQUENCE trial design consisted of randomizing patients with moderate to severe CD who have failed TNF therapy to two treatments arms, an IL-23 inhibitor and an IL-12/23 inhibitor with a goal of assessing both clinical and endoscopic endpoints.